Wolfe, A. R., Prabhakar, D., Yildiz, V. O., Cloyd, J. M., Dillhoff, M., Abushahin, L., . . . Williams, T. M. Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Wiley.
Chicago Style (17th ed.) CitationWolfe, Adam R., et al. Neoadjuvant‐modified FOLFIRINOX Vs Nab‐paclitaxel Plus Gemcitabine for Borderline Resectable or Locally Advanced Pancreatic Cancer Patients Who Achieved Surgical Resection. Wiley.
MLA (9th ed.) CitationWolfe, Adam R., et al. Neoadjuvant‐modified FOLFIRINOX Vs Nab‐paclitaxel Plus Gemcitabine for Borderline Resectable or Locally Advanced Pancreatic Cancer Patients Who Achieved Surgical Resection. Wiley.
Warning: These citations may not always be 100% accurate.